Certara to Participate in the William Blair Growth Stock Conference and Jefferies Virtual Healthcare Conference
Certara, Inc. (Nasdaq: CERT) announced participation in upcoming virtual investor conferences featuring CEO William Feehery and CFO Andrew Schemick.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Certara, Inc. (Nasdaq: CERT) announced participation in upcoming virtual investor conferences featuring CEO William Feehery and CFO Andrew Schemick. They will speak at William Blair's 41st Annual Growth Stock Conference on June 1 at 11:40 a.m. ET and the Jefferies Virtual Healthcare Conference on June 4 at 10:00 a.m. ET. Live webcasts will be available on Certara's investor relations website and can be replayed for 90 days. Certara specializes in biosimulation software to enhance drug discovery and development for over 1,650 global clients.
Details
News Market Reaction – CERT
The recorded move for CERT in the trading session of this news was +3.25%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PRINCETON, N.J., May 20, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that William Feehery, Chief Executive Officer, and Andrew Schemick, Chief Financial Officer, will participate in the following virtual investor conferences:
- William Blair's 41st Annual Growth Stock Conference
Fireside Chat on Tuesday, June 1st at 11:40 a.m. ET
- Jefferies Virtual Healthcare Conference
Fireside Chat on Friday, June 4th at 10:00 a.m. ET
Live webcasts will be available on Certara’s investor relations website at https://ir.certara.com and will be available for replay for 90 days thereafter.
About Certara
Certara accelerates medicines using biosimulation software and technology to transform traditional drug discovery and development. Its clients include more than 1,650 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 61 countries.
Investor Relations Contact:
David Deuchler
Gilmartin Group
ir@certara.com
Media Contact:
Ariane Lovell
Finn Partners
ariane.lovell@finnpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.